{"DataElement":{"publicId":"3009205","version":"2","preferredName":"Disease or Disorder Best Outcome of Therapy Amyloidosis Hematologic Status Type","preferredDefinition":"A description of the best hematologic response to therapy for amyloidosis.","longName":"2946463v1.0:3009199v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3009199","version":"1.1","preferredName":"Amyloidosis Hematologic Status Type","preferredDefinition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands._Pertaining to or related to the blood and blood-forming organs._A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"3009199v1.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Continued complete response (CCR)","valueDescription":"Continued complete response","ValueMeaning":{"publicId":"6769541","version":"1","preferredName":"Continued complete response","longName":"6769541","preferredDefinition":"For recipients already in CR prior to the start of the preparative regimen","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89A36892-10D6-64AD-E053-F662850A9C1A","latestVersionIndicator":"Yes","beginDate":"2019-05-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-24","modifiedBy":"ONEDATA","dateModified":"2019-05-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89A36892-10EE-64AD-E053-F662850A9C1A","beginDate":"2019-05-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-24","modifiedBy":"ONEDATA","dateModified":"2019-05-24","deletedIndicator":"No"},{"value":"Partial response (PR)","valueDescription":"Partial response","ValueMeaning":{"publicId":"4241993","version":"1","preferredName":"Partial response","longName":"4241993","preferredDefinition":"A greater than 50% reduction in the dFLC (difference between serum involved free light and uninvolved serum free light chain)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50F7DB8-83C2-F95E-E040-BB89AD431F15","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"HARTLEYG","dateModified":"2019-05-16","changeDescription":"Changed per request of Angela Kummerow; 05.16.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89022ADE-FF20-4DDF-E053-F662850AF3C3","beginDate":"2011-03-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"No response (NR) / stable disease (SD)","valueDescription":"No response/stable disease","ValueMeaning":{"publicId":"4241991","version":"1","preferredName":"No response/stable disease","longName":"4241991","preferredDefinition":"Less than a PR","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50F7DB8-8373-F95E-E040-BB89AD431F15","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"HARTLEYG","dateModified":"2019-05-16","changeDescription":"Changed per request by Angela Kummerow, 05.16.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89022ADE-FF34-4DDF-E053-F662850AF3C3","beginDate":"2014-03-20","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"5682944","version":"1","preferredName":"Unknown","longName":"5682944","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AE5-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"GDEEN","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89000172-AE3D-29F8-E053-F662850AB9E0","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Relapse from CR (Rel) (untreated)","valueDescription":"Relapse from CR","ValueMeaning":{"publicId":"6757623","version":"1","preferredName":"Relapse from CR","longName":"6757623","preferredDefinition":"From CR, any detectable monoclonal protein or abnormal free light chain ratio (light chain must double)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89000172-AE47-29F8-E053-F662850AB9E0","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89000172-AE60-29F8-E053-F662850AB9E0","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Very good partial response (VGPR)","valueDescription":"Very good partial response","ValueMeaning":{"publicId":"6757624","version":"1","preferredName":"Very good partial response","longName":"6757624","preferredDefinition":"Reduction in the dFLC (difference between involved serum free light and uninvolved serum free light chain) to < 40 mg/l","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"89000172-AE6A-29F8-E053-F662850AB9E0","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89000172-AE82-29F8-E053-F662850AB9E0","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Complete response (CR)","valueDescription":"Complete response","ValueMeaning":{"publicId":"4241992","version":"1","preferredName":"Complete response","longName":"4241992","preferredDefinition":"Normalization of the free serum light chain level and ratio, negative serum and urine immunofixation","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F50F7DB8-83A0-F95E-E040-BB89AD431F15","latestVersionIndicator":"Yes","beginDate":"2014-03-20","endDate":null,"createdBy":"SORENSENS","dateCreated":"2014-03-20","modifiedBy":"HARTLEYG","dateModified":"2019-05-16","changeDescription":"Changed per request by Angela Kummerow, 05.16.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89000172-AE8C-29F8-E053-F662850AB9E0","beginDate":"2011-11-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"},{"value":"Progressive disease (PD)","valueDescription":"Progressive disease","ValueMeaning":{"publicId":"4871971","version":"1","preferredName":"Progressive disease","longName":"4871971","preferredDefinition":"From PR, 50% increase in serum M protein to > 0.5 g/dl or 50% increase in urine M protein to >200 mg/day (a visible peak must be present) and free light chain increase of 50% to > 100 mg","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18B7C7FC-C7AA-F153-E050-BB89AD437E4D","latestVersionIndicator":"Yes","beginDate":"2015-06-17","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-06-17","modifiedBy":"HARTLEYG","dateModified":"2019-05-16","changeDescription":"Changed per request of Angela Kummerow, 05.16.19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"89000172-AEA0-29F8-E053-F662850AB9E0","beginDate":"2011-03-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"ONEDATA","dateModified":"2019-05-16","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3009198","version":"1","preferredName":"Amyloidosis Hematologic Status Type","preferredDefinition":"A group of diseases in which protein is deposited in specific organs (localized amyloidosis) or throughout the body (systemic amyloidosis). Amyloidosis may be either primary (with no known cause) or secondary (caused by another disease, including some types of cancer). Generally, primary amyloidosis affects the nerves, skin, tongue, joints, heart, and liver; secondary amyloidosis often affects the spleen, kidneys, liver, and adrenal glands.:Pertaining to or related to the blood and blood-forming organs.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C2868:C62780:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Amyloidosis","conceptCode":"C2868","definition":"A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Hematologic","conceptCode":"C62780","definition":"Pertaining to or related to the blood and blood-forming organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F57A4E6-FEDC-4596-E040-BB89AD432406","latestVersionIndicator":"Yes","beginDate":"2010-02-11","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-11","modifiedBy":"ONEDATA","dateModified":"2010-02-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"89022ADE-FEEB-4DDF-E053-F662850AF3C3","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964910","version":"1","longName":"2117r1: Amyloidosis Post-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PCDpost_amy_hema_organ_hema_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the best hematologic","type":"Preferred Question Text","description":"What was the best hematologic outcome of therapy for amyloidosis?","url":null,"context":"NHLBI"},{"name":"What was the best response to  HSCT?","type":"Alternate Question Text","description":"What was the best response to  HSCT?","url":null,"context":"NHLBI"},{"name":"What was the best hematologic response to therapy?","type":"Alternate Question Text","description":"What was the best hematologic response to therapy?","url":null,"context":"NHLBI"},{"name":"Specify the best hematologic response:","type":"Alternate Question Text","description":"Specify the best hematologic response:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3009205","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"hematologic disorder\"","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best hematologic response to the HCT","type":"Alternate Question Text","description":"Specify the recipient's best hematologic response to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best hematologic response to the HCT","type":"Application Standard Question Text","description":"Specify the recipient's best hematologic response to the HCT","url":null,"context":"NHLBI"},{"name":"Specify the recipient's best hematologic response to the HSCT","type":"Alternate Question Text","description":"Specify the recipient's best hematologic response to the HSCT","url":null,"context":"NHLBI"},{"name":"Best hematologic response to line of therapy","type":"Alternate Question Text","description":"Best hematologic response to line of therapy","url":null,"context":"NHLBI"},{"name":"For recipients with primary disease or concurrent / history of Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"For recipients with primary disease or concurrent / history of Amyloidosis, compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"Compared to the disease status prior to the preparative regimen, what was the best hematologic response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"88F104AF-8A17-0A90-E053-F662850AFD89","latestVersionIndicator":"Yes","beginDate":"2019-05-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-05-16","modifiedBy":"KUMMEROA","dateModified":"2020-02-03","changeDescription":". System generated def displayed as alt def.; System generated def displayed as alt def. Added AQT for 2116. AK 8/28/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}